Astrazeneca

FromAstraZeneca ([email protected])
Subject (50)Fixed-duration Calquence approved in EU for 1L CLL
Preheader (126)Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting
Typography
Arial
Colors
Text Analysis
Body Words123
Subject Words8
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px734 px
X-Spam Score-0.2
Preheader OptimizedNo
Timing
Day of WeekThursday
TimeOvernight

Fixed-duration Calquence approved in EU for 1L CLL

Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting
Fixed-duration Calquence approved in EU for 1L CLL